The global platelet aggregation devices market is poised to reach a value of $342.4 Million by 2020, growing at a CAGR of 21.0% from 2015 to 2020. Factors such as rising incidences of target diseases, rapid growth in the geriatric population across the globe, technological advancements in platelet aggregometers, and increasing number of industry-academia collaborations and clinical studies are fueling the growth of the global market. However, procedural limitations, unfavorable healthcare reforms in the U.S., and dearth of well trained and skilled professionals are some of the key factors restraining the growth of this market.

North America (particularly the U.S.) is poised to be the fastest growing region in global platelet aggregation devices market during the forecast period. North American region has become attractive destination for companies engaged in the development, manufacture, and distribution of platelet aggregation products. Factors such as growing number of surgical procedures, rising awareness among healthcare professionals (related to the benefits offered by platelet aggregation testing in disease diagnosis), large number of patients undergoing cardiovascular surgeries, and increasing prevalence of orthopedic, urological, and bleeding disorders are offering high-growth opportunities for players active in the North American platelet aggregation devices market.

As of 2014, F. Hoffmann La-Roche Ltd. (Switzerland) dominated the global platelet aggregation devices market. Over the past three years, the company adopted new product launches and strategic partnerships, collaborations, and alliances as its key business strategies to maintain its position in the market. The other key players in this market are Haemonetics Corporation (U.S.), Sysmex Corporation (Japan), Siemens AG (Germany), Accriva Diagnostics (U.S.), Helena Laboratories Corporation (U.S.), Bio/Data Corporation (U.S.), Tem Group (Switzerland), Sentinel CH. S.p.A. (Italy), and Aggredyne, Inc. (U.S.).

Scope of the Report : Platelet Aggregation Devices Market

This research report categorizes the platelet aggregation devices market into the following segments and subsegments:

Market, by Product

Systems

Reagents

Consumables and Accessories

Market, by Application

Research Applications

Clinical Applications

Cardiovascular Applications

Orthopedic Applications

Other Clinical Applications (Bleeding Disorders, Antiplatelet Therapy, and Trauma)

Market, by End User

Standalone Hospitals

Diagnostic Laboratories

Research and Academic Institutes

Other End Users (Blood Banks and Pharmaceutical & Biotechnology Companies)

Market, by Region

North America U.S. Canada

Europe Germany France U.K. Rest of Europe

Asia-Pacific Japan China India Rest of Asia-Pacific

Rest of the World (RoW)

The global platelet aggregation devices market is poised to reach ~$342.4 Million by 2020, growing at a CAGR of 21.0% from 2015 to 2020. Market growth can be attributed to factors such as rising incidence of target diseases, rapid growth in the geriatric population across the globe, technological advancements in platelet aggregometers, and increasing number of industry-academia collaborations & clinical studies. However, factors such as procedural limitations, unfavorable healthcare reforms in the U.S., and dearth of well trained & skilled professionals are restraining the growth of this market. In addition, stringent regulatory policies and limited medical reimbursements are posing significant challenges for the growth of the market.

On the basis of product, the global platelet aggregation devices market is classified into three major segments, namely, instruments, reagents, and consumables & accessories. The Systems segment is expected to account for the largest share of the global market in 2015. This product segment is expected to grow at the highest CAGR in the next five years, owing to factors such as continuous technological advancements in the field of sensors and detectors, rising trend of automation of platelet aggregation testing procedures, growing adoption & market preference for automated instruments among diagnostic laboratories, and improved patient compliance offered by point-of-care testing analyzers as compared to conventional instruments.

On the basis of end user, the global platelet aggregation devices market is classified into standalone hospitals, diagnostic laboratories, research & academic institutes, and other end users (blood banks & pharmaceutical-biotechnology companies).Standalone hospitals segment is expected to account for the largest share of the global market in 2015. This segment is expected to grow at the highest CAGR in the next five years as well, owing to benefits offered by hospitals in conducting platelet aggregation testing procedure, large patient population base for target diseases (such as bleeding disorders, cardiovascular diseases, and arthritis), growing public-private investments for development and modernization of healthcare infrastructure, and increasing number of hospitals across developing countries.

Geographically, the platelet aggregation devices market is classified into four regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World. In 2015, the global market is expected to be dominated by North America. North American platelet aggregation devices market is also poised to grow at the highest CAGR owing to factors such as large patient population for target diseases (such as arthritis, leukemia, and hemophilia), strong presence of device manufacturers in the region, growing number of surgical procedures performed annually, growing awareness among healthcare professionals (related to the benefits offered by platelet aggregation testing in disease diagnosis), and availability of significant investments to support R&D programs that utilize platelet